Intestinal Research

Inflammatory Bowel Diseases
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI): Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano; Intest Res. 2021;19(4):386-397. Published online December 1, 2020; DOI: https://doi.org/10.5217/ir.2020.00080
Web of Science 17 Crossref 16; Full text PubReader ePub PDF Supplementary Material

Microbiota
Gut microbiome and checkpoint inhibitor colitis: Kanika Sehgal, Sahil Khanna; Intest Res. 2021;19(4):360-364. Published online December 1, 2020; DOI: https://doi.org/10.5217/ir.2020.00116
Web of Science 13 Crossref 13; Full text PubReader ePub PDF

Inflammatory Bowel Diseases
Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease: Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy; Intest Res. 2021;19(4):398-407. Published online November 20, 2020; DOI: https://doi.org/10.5217/ir.2020.00107
Web of Science 12 Crossref 11; Full text PubReader ePub PDF Supplementary Material

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study: Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi; Intest Res. 2021;19(4):419-429. Published online November 10, 2020; DOI: https://doi.org/10.5217/ir.2020.00033
Web of Science 12 Crossref 13; Full text PubReader ePub PDF

Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy: Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama; Intest Res. 2021;19(4):430-437. Published online November 9, 2020; DOI: https://doi.org/10.5217/ir.2020.00067
Web of Science 4 Crossref 5; Full text PubReader ePub PDF

High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis: Saransh Jain, Divya Namdeo, Pabitra Sahu, Saurabh Kedia, Peush Sahni, Prasenjit Das, Raju Sharma, Vipin Gupta, Govind Makharia, Lalit Dar, Simon PL Travis, Vineet Ahuja; Intest Res. 2021;19(4):438-447. Published online November 6, 2020; DOI: https://doi.org/10.5217/ir.2020.00055
Web of Science 7 Crossref 9; Full text PubReader ePub PDF Supplementary Material

IBD
Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment: Shintaro Akiyama, Victoria Rai, David T. Rubin; Intest Res. 2021;19(1):1-11. Published online November 5, 2020; DOI: https://doi.org/10.5217/ir.2020.00047
Web of Science 17 Crossref 20; Full text PubReader ePub PDF

Inflammatory Bowel Diseases
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study: Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul; Intest Res. 2021;19(1):71-82. Published online September 4, 2020; DOI: https://doi.org/10.5217/ir.2019.09159
Web of Science 16 Crossref 17; Full text PubReader ePub PDF Supplementary Material

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?: Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis; Intest Res. 2021;19(4):461-467. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00042
Web of Science 6 Crossref 5; Full text PubReader ePub PDF

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis: Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi; Intest Res. 2021;19(4):448-460. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00026
Web of Science 9 Crossref 10; Full text PubReader ePub PDF Supplementary Material

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis: Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee; Intest Res. 2021;19(3):323-331. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00039
Web of Science 22 Crossref 23; Full text PubReader ePub PDF

Trends of inflammatory bowel disease at a tertiary care center in northern India: Ajit Sood, Kirandeep Kaur, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Namita Bansal, Varun Mehta, Dharmatma Singh; Intest Res. 2021;19(3):282-290. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00010
Web of Science 12 Crossref 10; Full text PubReader ePub PDF Supplementary Material

Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018: Satimai Aniwan, Julajak Limsrivilai, Supot Pongprasobchai, Nonthalee Pausawasdi, Piyapan Prueksapanich, Natanong Kongtub, Rungsun Rerknimitr; Intest Res. 2021;19(2):186-193. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00028
Web of Science 12 Crossref 12; Full text PubReader ePub PDF

Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry: Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao; Intest Res. 2021;19(2):206-216. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09169
Web of Science 19 Crossref 20; Full text PubReader ePub PDF

Inflammatory bowel diseases
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease: Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh; Intest Res. 2020;18(4):355-378. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09176
Web of Science 12 Crossref 12; Full text PubReader ePub PDF

Search